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Mild cognitive impairment in Parkinson’s disease is associated with progression to dementia (Parkinson’s disease dementia) in a
majority of patients. Determining structural imaging biomarkers associated with prodromal Parkinson’s disease dementia may
allow for the earlier identiﬁcation of those at risk, and allow for targeted disease modifying therapies. One hundred and ﬁve non-
demented subjects with newly diagnosed idiopathic Parkinson’s disease and 37 healthy matched controls had serial 3T structural
magnetic resonance imaging scans with clinical and neuropsychological assessments at baseline, which were repeated after
18 months. The Movement Disorder Society Task Force criteria were used to classify the Parkinson’s disease subjects into
Parkinson’s disease with mild cognitive impairment (n = 39) and Parkinson’s disease with no cognitive impairment (n = 66).
Freesurfer image processing software was used to measure cortical thickness and subcortical volumes at baseline and follow-up.
We compared regional percentage change of cortical thinning and subcortical atrophy over 18 months. At baseline, cases with
Parkinson’s disease with mild cognitive impairment demonstrated widespread cortical thinning relative to controls and atrophy of
the nucleus accumbens compared to both controls and subjects with Parkinson’s disease with no cognitive impairment. Regional
cortical thickness at baseline was correlated with global cognition in the combined Parkinson’s disease cohort. Over 18 months,
patients with Parkinson’s disease with mild cognitive impairment demonstrated more severe cortical thinning in frontal and
temporo-parietal cortices, including hippocampal atrophy, relative to those with Parkinson’s disease and no cognitive impairment
and healthy controls, whereas subjects with Parkinson’s disease and no cognitive impairment showed more severe frontal cortical
thinning compared to healthy controls. At baseline, Parkinson’s disease with no cognitive impairment converters showed bilateral
temporal cortex thinning relative to the Parkinson’s disease with no cognitive impairment stable subjects. Although loss of both
cortical and subcortical volume occurs in non-demented Parkinson’s disease, our longitudinal analyses revealed that Parkinson’s
disease with mild cognitive impairment shows more extensive atrophy and greater percentage of cortical thinning compared to
Parkinson’s disease with no cognitive impairment. In particular, an extension of cortical thinning in the temporo-parietal regions in
addition to frontal atrophy could be a biomarker in therapeutic studies of mild cognitive impairment in Parkinson’s disease for
progression towards dementia.
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Introduction
Parkinson’s disease is a progressive neurodegenerative dis-
order affecting over 4 million people worldwide above the
age of 50, with a prevalence that is expected to double to
9.3 million by 2030 (Dorsey et al., 2007). There has been a
gradual shift in the deﬁnition of Parkinson’s disease, from a
classical akinetic-rigid movement disorder to a complex
multi-system neurodegenerative disease affecting multiple
cognitive domains (Yarnall et al., 2014) with debilitating
consequences for patients (Lawson et al., 2014) and care-
givers (Aarsland et al., 1999). Cognitive deﬁcits are fre-
quent comorbidities in Parkinson’s disease, with up to
80% of patients with Parkinson’s disease eventually
developing mild cognitive impairment (PD-MCI) and
dementia (Parkinson’s disease dementia) (Aarsland et al.,
2003).
The neural substrates of cognitive impairment in
Parkinson’s disease remain only partially understood and
underscore the need to establish imaging biomarkers that
are capable of aiding the identiﬁcation of ‘at risk’ patients
for dementia and by so doing help in their early diagnosis
and treatment. Previous voxel-based morphometric (VBM)
studies have found detected atrophy in the temporal,
parietal and frontal cortices in PD-MCI compared to
Parkinson’s disease with no cognitive impairment
(PD-NC) (Song et al., 2011; Melzer et al., 2012). These
anatomical changes were mirrored by neurocognitive func-
tional abnormalities (Nombela et al., 2014). At a subcor-
tical level, reduced volumes of the hippocampus, thalamus
and the nucleus accumbens have also been reported in
PD-MCI (Weintraub et al., 2011; Mak et al., 2014).
However, a consensus concerning the presence of grey
matter atrophy in PD-MCI remains to be established
(Apostolova et al., 2010; Dalaker et al., 2010; Hattori
et al., 2012). A previous VBM study with a large sample
of 148 subjects with Parkinson’s disease did not reveal any
signiﬁcant grey matter atrophy in PD-MCI compared with
healthy controls (Pereira et al., 2012). It is possible that
these negative ﬁndings may reﬂect inadequate sensitivity
of VBM for detecting subtle cortical atrophy in the early
stages of Parkinson’s disease (Jubault et al., 2011).
Alternatively it could be that the different types of
PD-MCI have differing neurobiological substrates
(Williams-Gray et al., 2009). Finally, surface-based analyses
of cortical thickness may prove to be more sensitive than
VBM (Pereira et al., 2012), as there is evidence from corti-
cometry studies showing cortical thinning in temporal and
parietal regions in PD-MCI relative to PD-NC
(Pagonabarraga et al., 2013; Pereira et al., 2014; Segura
et al., 2014).
The search for potential imaging biomarkers of cognitive
impairment in Parkinson’s disease has also been hindered
by a scarcity of longitudinal evidence. Beyond inherent
challenges in interpretations of causality, cross-sectional
measurements may be less sensitive as subtle changes
tend to be masked by large interindividual variability in
brain size and structure, which could in turn account for
the inconsistent ﬁndings. With serial imaging, the subject
serves as his or her own reference point, allowing the
investigation of the spatio-temporal progression of
cortical thinning to be quantiﬁed at the individual level,
and in turn, provide insights into the vulnerability of
certain brain regions as well as their trajectory of atrophy
in the disease course of Parkinson’s disease.
In this study, we have investigated regional cortical
thickness and subcortical volumes in a large and well-
characterized cohort of non-demented subject with
Parkinson’s disease. Subjects were classiﬁed into
PD-MCI and PD-NC using the Movement Disorders
Society (MDS) diagnostic criteria (Litvan et al., 2012).
Importantly, we evaluated the progression of cortical
thinning and subcortical atrophy using serial MRI over
18 months. We hypothesized that PD-MCI would be
characterized by signiﬁcantly reduced cortical thickness
at baseline and develop a more severe pattern of cor-
tical thinning compared to PD-NC and healthy controls
over time.
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Materials and methods
Participants
Between June 2009 and December 2011, patients with newly
diagnosed Parkinson’s disease from community and outpatient
clinics in the North East of England were recruited (n = 128)
and followed up for 18 months. Over the course of the study,
18 subjects with Parkinson’s disease did not return for follow-
up (15 withdrawn and three deceased) and two subjects were
excluded due to a change in their diagnosis, who did not differ
signiﬁcantly from included Parkinson’s disease subjects in
terms of age and Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS). Only subjects (n = 108) with baseline and follow-
up assessments were included in this study. Written requests
for notiﬁcation of patient details were sought from all general
practitioners, neurologists, geriatricians and Parkinson’s dis-
ease specialist nurses. Parkinson’s disease was diagnosed by a
movement disorders specialist according to the UK Brain Bank
criteria (Hughes, 2002). Full inclusion and exclusion criteria
have been previously described (Khoo et al., 2013; Nombela
et al., 2014; Yarnall et al., 2014). Speciﬁcally, subjects with
dementia at presentation (DSM IV criteria for dementia or
MDS criteria for dementia) were excluded. Additionally, sub-
jective cognitive decline and functional independence of par-
ticipants were determined through semi-structured interviews
with participants and/or their carers for the classiﬁcation of
dementia as well as PD-MCI. Unrelated healthy controls
(n = 50) of similar age and sex to patients were recruited
from community sources to control for normal ageing.
Twelve healthy controls did not return for follow-up (11 with-
drawn and one deceased) who were not signiﬁcantly different
in age. This resulted in a ﬁnal sample size of 38 healthy con-
trols with both baseline and follow-up scans.
Standard protocol approvals,
registrations and patient consents
The study was approved by the Newcastle and North Tyneside
Research Ethics Committee. All subjects provided written
informed consent.
Clinical assessment
Clinical and demographic data were collected, including dis-
ease duration, level of education, medication and family his-
tory. Clinical assessments were performed by trained
examiners, and included a standardized neurological examin-
ation, the Geriatric Depression Scale (Yesavage et al., 1982),
the revised Uniﬁed Parkinson’s Disease Rating Scale (UPDRS
III) (Goetz et al., 2008), and Hoehn and Yahr staging (Hoehn
and Yahr, 2001).
Neuropsychological assessment
In line with MDS Task Force recommendations (Litvan et al.,
2012), ﬁve cognitive domains were assessed. Attention was
measured using the Cognitive Drug Research computerized
battery (Wesnes et al., 2002). Mean response times of simple
reaction time, choice reaction time, and digit vigilance were
summed to produce a Power of Attention score. Digit vigilance
accuracy was also evaluated as part of this domain. Memory
was assessed with Pattern Recognition Memory (PRM), Spatial
Recognition Memory (SRM), and Paired Associates Learning
(PAL) from the computerized Cambridge Neuropsychological
Test Automated Battery (CANTAB) (Fray and Robbins, 1996).
Executive function was determined using the modiﬁed
‘One Touch Stockings’ (OTS) version of the Tower of
London task from the CANTAB battery, phonemic ﬂuency
(words beginning with ‘F’ in 1min) and semantic ﬂuency (ani-
mals in 90 s). The pentagon copying item of the Mini-Mental
State Examination (MMSE) was graded using a modiﬁed 0 to
2 rating scale as a measure of visuospatial function.
Language domain was assessed using the naming (0–3) and
sentence (0–2) subsets of the Montreal Cognitive Assessment
(MoCA) test.
All participants were assessed ‘ON’ their usual dopaminergic
medication at baseline and 18 months. Levodopa equivalent
daily dose value was calculated using the Tomlinson et al.
(2010) formula. Global cognitive function was assessed using
the MMSE (Folstein et al., 1975) and the MoCA (Dalrymple-
Alford et al., 2010). Performance on the individual tasks was
transformed into z-scores. Subsequently, a composite summary
index for each cognitive domain was derived from the corres-
ponding averages of the respective neuropsychological tests.
A subject was diagnosed as PD-MCI if they were impaired
(1.5 SDs) below normative means on two tests in one cognitive
domain or on one test in two different domains (i.e. impair-
ment on any two tests). Consistent with previous studies
(Pereira et al., 2014; Yarnall et al., 2014), modiﬁed level 2
criteria were used as our neuropsychological battery predated
the publication of the PD-MCI criteria, in that only one test
was speciﬁc to the visuospatial domain. Within the Parkinson’s
disease group, 40 subjects were classiﬁed as PD-MCI while the
remaining Parkinson’s disease subjects were classiﬁed as
PD-NC (n = 68).
MRI acquisition
Subjects underwent both baseline and repeat MRI with an
18-month interval. Both MRI acquisitions were done on the
same 3T MRI system (Intera Achieva scanner, Philips Medical
Systems). The structural scans were acquired using a standard
T1-weighted volumetric sequence covering the whole brain:
3D magnetization-prepared rapid gradient echo sequence
(MPRAGE), sagittal acquisition, echo time = 4.6ms, repetition
time = 9.6ms, inversion time 1250ms, ﬂip angle = 8, SENSE
factor = 2, in-plane ﬁeld of view 240  240mm yielding a
voxel size of 1.15  1.15mm with slice thickness of 1.2mm.
Preprocessing of baseline and
longitudinal imaging data
Cortical reconstruction and volumetric segmentation of MRI
data was performed using the Freesurfer 5.3 image analysis
suite (http://surfer.nmr.mgh.harvard.edu/) using standard
methods (Fischl et al., 1999; Fischl and Dale, 2000). The initial
processing of T1 MRI images, for each subject and each time
point (baseline and follow-up), includes the following steps:
removal of non-brain tissue, automated Talairach transform-
ation, segmentation of the subcortical white matter and deep
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grey matter volumetric structures, intensity normalization, tes-
sellation of the grey matter/white matter boundary, automated
topology correction and surface deformation to optimally
place the grey matter/white matter and grey matter/CSF
boundaries. The cortical thickness was calculated as the closest
distance from the grey/white matter boundary to the grey/CSF
boundary at each vertex.
For the longitudinal processing, an unbiased within-subject
template (Reuter and Fischl, 2011) was created using robust,
inverse consistent registration between the two time points
(Reuter et al., 2010). Several processing steps, such as skull
stripping, Talairach transformations, atlas registration, as well
as spherical surface maps and parcellations were initialized
with common information from the within-subject template,
signiﬁcantly increasing reliability and statistical power
(Reuter et al., 2012). To facilitate the comparison of our
ﬁndings, the cortical thickness maps were smoothed using a
15mm full-width half-maximum Gaussian that is also
consistent with the majority of recent cortical thickness studies
in Parkinson’s disease (Ibarretxe-Bilbao et al., 2012; Pereira
et al., 2012, 2014; Garcia-Diaz et al., 2014; Segura et al.,
2014). All surface models in our study were visually inspected
for accuracy and manual corrections were performed in
the event of tissue misclassiﬁcation/white matter errors
while blinded to diagnostic group information. Subjects who
had excessive pial/white matter surface segmentation
errors after the manual correction were excluded from
the subsequent baseline (one healthy control, two PD-
NC, one PD-MCI) and follow-up (three PD-NC) statistical
analyses.
Baseline and longitudinal
comparisons of cortical thickness
Baseline comparisons between groups were assessed using a
vertex-wise general linear model (GLM). The model included
cortical thickness as a dependent factor and diagnostic group
(healthy controls, PD-NC, and PD-MCI) as an independent
factor. Analyses were performed to determine the association
between regional cortical thickness and cognitive function.
For the longitudinal analyses of cortical thinning, vertex-wise
comparisons of per cent change of cortical thickness among
the diagnostic groups were analysed using the longitudinal
two-stage GLM in Freesurfer (Reuter et al., 2012). In the
longitudinal analysis, the per cent change of cortical thickness
was the dependent factor and the diagnostic group was the
independent factor. We further investigated the association
between regional cortical thickness and longitudinal changes
in global cognition and the composite scores for speciﬁc cog-
nitive domains. In all GLM analyses, age, gender and educa-
tion were included as nuisance covariates while levodopa
equivalent daily dose was an additional covariate in the com-
parisons between PD-NC and PD-MCI groups. Consistent
with previous methodologies (Ibarretxe-Bilbao et al., 2012;
Garcia-Diaz et al., 2014; Segura et al., 2014), family wise
error (FWE) cluster-based correction using Monte Carlo simu-
lations with 10 000 iterations was applied to cortical thickness
maps to correct for multiple-comparisons and results were
thresholded at a corrected P-value of 0.05 (Hagler et al.,
2006).
Volumetric analysis of subcortical
structures
In addition, the following subcortical structures at both time-
points were automatically segmented from each hemisphere
using Freesurfer: thalamus, caudate, putamen, pallidum,
hippocampus, amygdala, and the nucleus accumbens.
Consistent with previous methodology (Mak et al., 2015),
we ﬁrst calculated the absolute difference in volumes
between both times [volumefollow-up volumebaseline] for
each subject before dividing by the volume at baseline
[volumefollow-up volumebaseline] / volumebaseline to normalize
the amount of atrophy with respect to baseline. This was
then multiplied by 100 to derive a percentage change score:
[volumefollow-up volumebaseline] / volumebaseline  100%.
Subsequently, group differences in percentage change of sub-
cortical volumes were interrogated with analysis of covariance
(ANCOVA) while controlling for age, gender, education and
the average of total intracranial volumes at both time points.
Post hoc Tukey-Kramer pairwise comparisons were subse-
quently performed between each group. Associations of sub-
cortical volumes with cognitive measures were also assessed
with correlational tests at baseline and at follow-up.
Statistical analyses
Statistical analyses were performed with the STATA13 (http://
www.stata.com/) software. The distribution of continuous
variables was tested for normality using the Skewness-
Kurtosis test and visual inspection of histograms. Parametric
data were assessed using either t-tests or analysis of variance
(ANOVA) for continuous variables. For non-parametric data,
Kruskal-Wallis was used. 2 tests were used to examine differ-
ences between categorical measures. For each test statistic, a
two-tailed probability value of 50.05 was regarded as
signiﬁcant.
Results
Demographics and clinical variables
The demographic and clinical information for Parkinson’s
disease and control subjects are summarized in Table 1.
PD-MCI subjects were signiﬁcantly older than PD-NC sub-
jects (P = 0.001), although there were no signiﬁcant differ-
ences in age between PD-MCI and healthy controls
(P = 0.170) or between PD-NC and healthy controls
(P = 0.308). Groups were well-matched in terms of gender
(P = 0.251). Years of education were signiﬁcantly lower in
PD-MCI compared to healthy controls (P = 0.002) and PD-
NC (P50.001). Compared to PD-NC, levodopa equiva-
lent daily dose intake was signiﬁcantly higher in PD-MCI
(P5 0.001) at baseline but there were no signiﬁcant differ-
ences in levodopa equivalent daily dose intake at follow-up
and changes of dosage over 18 months. In addition, there
were no signiﬁcant differences in disease duration, Hoehn
and Yahr staging or UPDRS III scores at baseline as well as
change scores over 18 months (Table 1). There was a main
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effect of group on depression scores (Geriatric Depression
Scale) [F(2 139) = 8.78, P50.001]. Post hoc Tukey pair-
wise tests showed that both PD-NC (P = 0.002) and
PD-MCI (P5 0.001) groups had signiﬁcantly higher
Geriatric Depression Scale scores than healthy controls
although there was no signiﬁcant difference in mean
Geriatric Depression Scale scores between PD-NC and
PD-MCI. As would be expected, there was a main effect
of group on MMSE [F(2 139) = 17.79, P5 0.009] and
MoCA scores [F(2 127) = 29.67, P5 0.001] at baseline.
Post hoc Tukey pair-wise tests revealed that PD-MCI
scored signiﬁcantly poorer on both MMSE and MoCA
compared to PD-NC (P5 0.001) and healthy controls
(P50.001). There was no difference in MMSE and
MoCA between PD-NC and healthy controls. There was
a main effect of group on MMSE change scores
[F(2 135) = 4.94, P = 0.001] over 18 months. The decline
in MMSE scores was signiﬁcantly greater in PD-MCI
compared to PD-NC (P = 0.038) and healthy controls
(P = 0.010). PD-NC did not signiﬁcantly differ from healthy
controls in terms of MMSE decline (P = 0.677). There were
no signiﬁcant differences in change in the MoCA among
the groups [F(2 124) = 1.54, P = 0.218].
Clinical and imaging comparisons
between stable Parkinson’s disease
subjects and converters
Of the 66 PD-NC subjects, there were 17 converters clas-
siﬁed as PD-MCI at follow-up. We compared demograph-
ics, clinical characteristics, and cortical thickness measures
between those who remained cognitively stable (PD-stable)
and those who converted to PD-MCI (PD-converters). The
PD-NC subgroups did not signiﬁcantly differ in age
(P = 0.129), gender (P = 0.157), UPDRS III (P = 0.480),
Table 1 Baseline and longitudinal demographics and clinical characteristics
Healthy controls PD-NC PD-MCI P-value
n 37 66 39
Age (years) 65.7  7.2 62.9  9.9 69.4  8.8 0.002a
Age range 49.7–85.4 41.8–87.3 48.1–85.5
Gender (male, %) 21 (56.7) 41 (62.1) 29 (74.4) 0.3 h
Education (years) 13.9  3.9 13.8  3.5 11.6  3.5 0.001e
Disease duration (months) 24.2  4.6 24.9  5.1 0.5f
Levodopa equivalent daily dose
Baseline 143.1  110.1 248.7  152.6 50.001f
Follow-up 391.1  202.1 470.2  209.9 0.059g
Change 237.8  213.9 221.5  216.0 0.5f
Hoehn and Yahr
Baseline 1.9  0.7 2.1  0.6 0.1g
Follow-up 2.1  0.6 2.2  0.4 0.2f
Change 0.2  0.6 0.1  0.6 0.2f
UPDRS III
Baseline 25.3  10.9 29  10.9 0.1g
Follow-up 31.1  12.7 37.9  9.4 0.001f
Change 6.6  10.7 8.9  10.1 0.3g
MMSE
Baseline 29.4  1.0 29.1  0.8 28.1  1.4 50.001a,b,c, 0.4d
Follow-up 29.6  1.0 29.1  1.0 27.4  2.0 50.001a,b,c, 0.1d
Change 0.2  0.7 0.0  1.1 0.6  1.9 0.009a, 0.010b, 0.038c, 0.7d
MoCA
Baseline 27.6  2.2 26.9  2.4 23.1  3.6 50.001a,b,c, 0.4d
Follow-up 27.9  3.0 27.8  2.0 24.1  3.5 50.001a,b,c, 0.9d
Change 0.3  2.7 1.1  1.9 1.2  3.1 0.2a
Geriatric Depression Scale
Baseline 1.0  1.5 2.5  2.5 2.9  2.1 50.001a,b, 0.6c, 0.002d
Follow-up 1.2  2.0 2.6  2.9 3.2  2.6 50.001a, 0.004b, 0.5c, 0.042d
Change 0.2  1.8 0.0  2.7 0.2  1.9 0.8a
Scan interval (years) 1.7  0.1 1.5  0.1 1.5  0.0 50.001a,b,d, 0.6c
Values expressed as mean  1SD.
aANOVA = healthy controls, PD-NC, PD-MCI.
Post hoc Tukey pairwse tests: bPD-MCI versus healthy controls; cPD-MCI versus PD-NC; d PD-NC versus healthy controls.
eKruskal-Wallis test.
fWilcoxon rank-sum test = PD-NC and PD-MCI.
gStudent’s t-test – PD-NC and PD-MCI.
h2 = PD-NC, PD-MCI, Controls.
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and levodopa equivalent daily dose intake (P = 0.292) at
baseline. However, PD-converters performed signiﬁcantly
less well on the MoCA (P = 0.039) and the MMSE at
trend level (P = 0.063) compared to the PD-stable group.
At baseline, we observed a bilateral pattern of cortical thin-
ning affecting the temporal regions in the PD-converters
relative to the PD-stable subjects. However, these signiﬁ-
cant ﬁndings did not survive after correcting for age,
gender, education, and levodopa equivalent daily dose
intake because of low power.
Baseline and longitudinal cortical
thinning
PD-MCI subjects versus healthy controls
At baseline, subjects with PD-MCI showed signiﬁcantly
reduced cortical thickness in the frontal, parietal and
occipital cortices: left supramarginal cortex, bilateral rostral
middle frontal cortex, left isthmus cingulate and right pos-
terior cingulate cortices, and the right lateral occipital
cortex (Fig.1 and Supplementary Table 1; P5 0.05; FWE
Monte Carlo cluster-wise corrected). Over 18 months, sub-
jects with PD-MCI had signiﬁcantly increased percentage of
cortical thinning predominantly in the frontal and parietal
cortices: left superior frontal cortex, left supramarginal
cortex, and right precuneus (Fig. 2 and Supplementary
Table 2; P5 0.05; FWE Monte Carlo cluster-wise
corrected).
PD-NC subjects versus healthy controls
At baseline, there were no signiﬁcant differences in regional
cortical thickness between PD-NC and healthy controls.
Over 18 months, however, PD-NC subjects developed a
signiﬁcantly greater percentage of cortical thinning in the
left caudal middle frontal cortex (Fig. 2 and Supplementary
Table 2; P5 0.05; FWE Monte Carlo cluster-wise
corrected).
PD-MCI versus PD-NC subjects
At baseline, there were no signiﬁcant differences in regional
cortical thickness between PD-MCI and PD-NC. Over
18 months, compared to the PD-NC group, the PD-MCI
subjects showed a signiﬁcantly greater percentage of cor-
tical thinning in the frontal and temporal cortices including
the left caudal middle frontal, right superior frontal cortex
and left superior temporal cortex. Compared to PD-MCI,
no increased percentage changes of cortical thinning were
found in the PD-NC group (Fig. 2 and Supplementary
Table 2; P5 0.05; FWE Monte Carlo cluster-wise
corrected).
Clinical and cognitive associations of cortical
thinning
Within the combined group of non-demented Parkinson’s
disease (PD-NC and PD-MCI), analyses with the MoCA
revealed a signiﬁcant positive association with baseline
cortical thickness, indicating that increased cortical thick-
ness was correlated with higher MoCA scores, in frontal
and temporo-parietal cortices: left fusiform gyrus, left
superior frontal cortex, left inferior parietal cortex, left
orbitofrontal cortex and right parahippocampal gyrus
(Fig. 3 and Supplementary Table 4; P5 0.05; FWE
Monte Carlo cluster-wise corrected).
Baseline and longitudinal comparisons of subcortical
atrophy in Parkinson’s disease
Table 2 shows the baseline comparisons of left and right
subcortical structures and the percentage change in volumes
between baseline and follow-up, and all P-values were un-
corrected for the number of subcortical structures (2  7).
At baseline, the left nucleus accumbens showed signiﬁcant
atrophy in the PD-MCI group compared to PD-NC
(P = 0.05) and at trend level relative to healthy controls
(P = 0.06). The PD-MCI group also had signiﬁcant atrophy
of the left hippocampus relative to PD-NC (P = 0.03). Over
18 months, the PD-MCI group demonstrated signiﬁcantly
greater atrophy of the left caudate relative to the healthy
controls (P = 0.04). We also found greater atrophy over
time in the right hippocampus of the PD-MCI compared
to both healthy controls (P = 0.04) and PD-NC (P = 0.03).
No signiﬁcant associations were found between subcortical
volumes and cognitive tests.
Discussion
The key ﬁndings in relation to our hypotheses are as
follows: (i) at baseline, PD-MCI is characterized by reduced
cortical thickness in both frontal and temporo-parietal
cortices with atrophy of the nucleus accumbens and the
hippocampus; (ii) compared to PD-NC and healthy con-
trols, PD-MCI developed an increased percentage of cor-
tical thinning in frontal and temporo-parietal cortices as
well as progressive hippocampal and caudate atrophy
over 18 months; (iii) PD-NC cases who converted to
PD-MCI over 18 months had temporal cortex thinning at
baseline; and (iv) although regional cortical thickness was
comparable in the entire PD-NC cohort and healthy con-
trols at baseline, the PD-NC cases subsequently developed
signiﬁcant frontal cortical thinning over 18 months.
Previous cross-sectional imaging studies of cortical thick-
ness in early Parkinson’s disease have yielded inconclusive
ﬁndings (Zarei et al., 2013; Mak et al., 2014) and earlier
longitudinal studies have only assessed global measures
such as whole brain atrophy rates (Burton et al., 2005).
To date, the only two previous longitudinal studies in
cortical thickness have been limited by their relatively
small sample size (Hanganu et al., 2014) and heteroge-
neous Parkinson’s disease cohorts (Ibarretxe-Bilbao et al.,
2012). Ibarretxe-Bilbao and colleagues found that non-
demented Parkinson’s disease subjects had more progres-
sive cortical thinning than controls with a bilateral
fronto-temporal pattern, extending to the parietal cortex
Longitudinal brain atrophy in PD-MCI BRAIN 2015: 138; 2974–2986 | 2979
 by guest on February 5, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
(Ibarretxe-Bilbao et al., 2012). Another study reported
faster rates of cortical thinning in the frontal and temporal
cortices, as well as the insular and supplementary motor
areas (Hanganu et al., 2014).
In the present study, we evaluated baseline cortical thick-
ness and subsequently compared the progression of cortical
thinning as well as subcortical atrophy over 18 months in a
large and well-characterized cohort of non-demented
Parkinson’s disease subjects and healthy controls. The pre-
sent study also extended the literature as our Parkinson’s
disease cohort was further classiﬁed into PD-MCI and PD-
NC based on the formal MDS criteria.
Figure 1 Reduced regional cortical thickness in PD-MCI compared to healthy controls at baseline. No significant differences in
baseline cortical thickness were found between PD-MCI and PD-NC, and between PD-NC and healthy controls. The colour bar shows the
logarithmic scale of P-values (log10).
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At baseline, PD-NC did not differ signiﬁcantly from
healthy controls in relation to cortical thickness though a
subgroup who subsequently converted to PD-MCI showed
temporal cortex thinning. Our results are in broad agree-
ment with several previous studies (Dalaker et al., 2010;
Ibarretxe-Bilbao et al., 2012; Melzer et al., 2012; Zarei
et al., 2013). Other studies have demonstrated reduced cor-
tical thickness in PD-NC compared to healthy controls
(Rowe et al., 2010; Pereira et al., 2014). Several reasons
may account for these discordant ﬁndings in the literature,
including heterogeneity in the PD-NC sample, especially in
relation to their stage of disease, and variability in the use
of different techniques assessing grey matter changes.
Compared to healthy controls, the morphological proﬁle
of structural changes was more widespread in PD-MCI
subjects with cortical thinning spanning across the frontal,
parietal, and occipital cortex as well as the cingulate cortex.
This extensive pattern of cortical thinning is in accordance
with previous studies (Hanganu et al., 2013; Pereira et al.,
2014; Segura et al., 2014). In addition, our results are also
consistent with a previous PET study that reported reduced
ﬂuorodeoxyglucose (FDG) uptake in the parietal and oc-
cipital lobes as well as localized areas of the frontal and
temporal lobes in PD-MCI (Garcia-Garcia et al., 2012).
As the implementation of the MDS Task Force diagnostic
criteria for PD-MCI in 2012, a limited number of studies
Figure 2 Vertex-wise comparisons of percentage change in cortical thinning over 18 months. (A) PD-MCI5HC; (B) PD-
NC5HC; (C) PD-MCI5 PD-NC. The colour bar shows the logarithmic scale of P-values (log10). Lh = left hemisphere; Rh = right
hemisphere.
Figure 3 Association between cognitive measures and regional cortical thickness at baseline. The colour bar shows the logarithmic
scale of P-values (log10). PD = Parkinson’s disease; Lh = left hemisphere; Rh = right hemisphere.
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have sought to determine its biological validity by deter-
mining structural differences in PD-MCI and PD-NC with-
out reaching a consensus: decreased cortical thickness has
been reported (Hanganu et al., 2013; Pereira et al., 2014),
while others have not observed any difference compared to
PD-NC (Mak et al., 2014; Segura et al., 2014). Here, we
did not detect any difference in baseline cortical thickness
between PD-MCI and PD-NC. Although this could be be-
cause early cognitive impairment results from functional
deﬁcit before cell loss, it may also be a false negative
with PD-NC lying intermediate between healthy controls
and PD-MCI.
At the subcortical level, there is accumulating evidence
that non-demented Parkinson’s disease is associated with
structural changes in the nucleus accumbens (Lee et al.,
2014). Another longitudinal study found a signiﬁcant
decrease of grey matter in the nucleus accumbens over
time in PD-MCI relative to PD-NC (Hanganu et al.,
2014). There is also evidence that atrophy of the nucleus
accumbens is predictive of cognitive decline in the elderly
(de Jong et al., 2012) and associated with depression
(Pizzagalli et al., 2009). In line with our observation of
higher depression scores in PD-MCI, previous studies
have reported that depression is more common in
PD-MCI than PD-NC (Monastero et al., 2013). These ﬁnd-
ings all suggest that the nucleus accumbens might be a
possible subcortical neural substrate for cognitive impair-
ment and neuropsychiatric symptoms in Parkinson’s
disease.
To overcome the limitation of past cross-sectional
approaches and to clarify previous inconclusive cross-
sectional ﬁndings of morphological changes in non-
demented Parkinson’s disease, the present study speciﬁcally
investigated regional rates of cortical thinning over 18
months. Despite demonstrating preserved cortical thickness
relative to healthy controls at baseline, the PD-NC group
subsequently developed signiﬁcant frontal cortical thinning
over the follow-up period. This ﬁnding is particularly note-
worthy in the absence of cognitive decline and raises two
important points: (i) progressive cortical thinning may pre-
cede signiﬁcant cognitive decline; and (ii) compensatory
functional mechanisms might be masking or buffering
against cognitive decline in our cohort of newly diagnosed
PD-NC subjects. Our longitudinal observation is also con-
sistent with previous reports of frontal thinning in PD-NC
compared to healthy controls at baseline (Tinaz et al.,
2011; Hanganu et al., 2013; Pagonabarraga et al., 2013).
In accordance with our hypothesis, the PD-MCI group
showed a greater percentage of cortical thinning in frontal
and temporo-parietal areas relative to both PD-NC and
healthy controls. These areas are commonly reported to
be atrophic in Parkinson’s disease dementia (Burton et al.,
2004; Beyer et al., 2007; Hwang et al., 2013). In agreement
with our observations of frontal involvement in PD-MCI at
baseline and over 18 months, a previous VBM study fol-
lowing a group of PD-MCI subjects over 2 years also found
that Parkinson’s disease dementia converters showed
increased frontal atrophy compared to non-converters
(Lee et al., 2014). Extending beyond the dorsal-lateral pre-
frontal cortex, the temporo-parietal pattern of cortical thin-
ning demonstrated by the PD-MCI group has also been
regarded as a marker of Alzheimer’s disease pathology
(Whitwell et al., 2011). As such, considering the transitory
stage of PD-MCI within the cognitive spectrum of
Parkinson’s disease, it is plausible to suggest that our lon-
gitudinal ﬁndings are heralding subsequent cognitive deteri-
oration and progression to Parkinson’s disease dementia.
The extended involvement from frontal regions in PD-
NC to the temporal regions observed in PD-MCI is also
consistent with prevailing theories of neurotransmitter
Table 2 Comparisons of subcortical volumes at baseline and longitudinal changes over 18 months
Hemisphere Subcortical
segmentations (ml)
Healthy controls PD-NC PD-MCI P-value
Baseline
volume
% change Baseline
volume
% change Baseline
volume
% change Baseline
volumea
%
changea
Left Thalamus 7.6  0.8 1.0  4.7 7.9  0.8 0.2  5.2 7.5  0.8 0.6  5.1 0.1 0.7
Caudate 3.4  0.5 1.0  4.9 3.5  0.5 1.2  4.9 3.6  0.7 2.5  8.8* 0.7 0.05
Putamen 4.7  0.6 1.0  7.7 4.8  0.7 1.2  5.8 4.7  0.7 2.0  7.1 0.9 0.1
Pallidum 1.5  0.2 1.3  9.0 1.5  0.2 0.4  10.3 1.5  0.2 1.4  8.6 0.7 0.5
Hippocampus 4.0  0.4 0.8  5.3 4.2  0.6 1.5  4.5 3.9  0.4 ** 3.2  6.0 0.04 0.2
Amygdala 1.4  0.2 1.8  7.1 1.5  0.2 0.4  8.1 1.4  0.2 2.5  6.7 0.8 0.3
Accumbens 0.4  0.1 0.9  25.1 0.4  0.1 0.3  23.7 0.37  0.1* 4.0  22.9 0.04 0.9
Right Thalamus 6.6  0.7 0.0  4.9 6.9  0.6 1.4  4.5 6.6  0.8 1.4  4.0 0.6 0.5
Caudate 3.1  0.5 0.4  4.3 3.3  0.4 2.1  7.3 3.3  0.5 2.0  6.8 0.4 0.6
Putamen 4.6  0.6 0.9  5.3 4.8  0.6 2.1  7.4 4.6  0.7 1.4  5.3 0.6 0.7
Pallidum 1.4  0.1 2.5  7.0 1.5  0.2 1.8  8.8 1.4  0.2 1.3  7.9 0.5 0.8
Hippocampus 4.1  0.5 1.7  4.2 4.3  0.5 1.7  4.7 4.0  0.5 5.3  8.9*** 0.2 0.02
Amygdala 1.5  0.2 1.2  11.0 1.6  0.2 2.2  9.0 1.5  0.2 7.0  15.4 0.1 0.1
Accumbens 0.5  0.1 0.3  13.0 0.5  0.1 1.3  13.2 0.5  0.1 2.0  13.6 0.1 0.9
Values expressed as mean  1 SD.
*PD-MCI5HC, **PD-MCI5 PD-NC, P5 0.05; ***PD-MCI5 PD-NC and healthy controls, P5 0.05.
aANCOVA = healthy controls, PD-NC, PD-MCI, correcting for age, gender, education, and intracerebral volume.
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deﬁcits underpinning cognitive dysfunction in Parkinson’s
disease. The focal pattern of increased frontal thinning
could be associated with concurrent disruption of dopamin-
ergic, serotonergic, cholinergic or noradrenergic frontal-
striatal circuits (Hilker et al., 2005; Calabresi et al.,
2006; Klein et al., 2010; Politis et al., 2010) as well as
cortical deafferentation as a result of white matter change
(Rae et al., 2012).
It is worth discussing our longitudinal ﬁndings in light of
a previous longitudinal cortical thickness study with a simi-
lar follow-up duration of 19.9 months (Hanganu et al.,
2014). Although our ﬁndings are congruent and share the
overarching conclusion that PD-MCI is characterized by
greater percentage of cortical thinning compared to
PD-NC and healthy controls, there were notable differences
in both the magnitude and spatial extent of cortical thin-
ning. Firstly, we did not ﬁnd signiﬁcant cortical thinning in
the occipital regions in PD-MCI, even though reduced cor-
tical thickness of the occipital region was present in
PD-MCI at baseline. Secondly, the previous study
(Hanganu et al., 2014) did not report any signiﬁcant dif-
ference in frontal regions between groups. Thirdly, fewer
peaks in the cortical thickness comparisons survived mul-
tiple comparisons. One likely explanation could be the rela-
tively smaller sample size (17 PD-MCI, 15 PD-NC, and 18
healthy controls) that would have limited the statistical
power of their cortical thickness analysis to reveal increased
thinning in frontal regions in PD-MCI.
Our longitudinal analyses of subcortical structures also
revealed signiﬁcant atrophy of both the caudate nucleus
and the hippocampus after 18 months in PD-MCI.
Although previous cross-sectional studies have found
reduced hippocampal volumes in PD-MCI (Weintraub
et al., 2011), our study is the ﬁrst to report increased pro-
gression of hippocampal atrophy in PD-MCI over time.
Together, these observations agree with histopathological
evidence indicating that the hippocampus is a target for
Lewy body inclusions in Parkinson’s disease, with particu-
lar vulnerability in the CA2 subﬁeld (Churchyard and Lees,
1997). Interestingly, the caudate nucleus also showed atro-
phy in the PD-MCI group over 18 months, possibly reﬂect-
ing dopamine deafferentation and consistent with the role
of dopaminergic disruption in cognitive impairment found
in Parkinson’s disease. A relationship between caudate
dopamine transporter (DAT) binding and cognition has
been reported (Polito et al., 2012) and longitudinal studies
have demonstrated that reduced baseline caudate DAT can
predict subsequent cognitive decline (Ravina et al., 2012).
The caudate nucleus, receiving dopaminergic inputs from
the substantia nigra, is interconnected with the dorsolateral
prefrontal cortex (Leh et al., 2007). Thus, through these
neuronal loops, dopaminergic deﬁcits could indirectly
impair frontal functions. Considered together, both our
longitudinal subcortical ﬁndings in PD-MCI confer support
to a previous cross-sectional ﬁnding that impaired cogni-
tion is related to caudate dopaminergic hypofunction as
well as hippocampal atrophy (Jokinen et al., 2009).
In summary, our joint investigation of baseline and lon-
gitudinal MRI measures in a well-delineated Parkinson’s
disease cohort allows us to integrate the ﬁndings into a
temporal and severity-gradient framework: at the time of
Parkinson’s disease diagnosis, frontal-striatal deﬁcits are
already prominent in PD-NC. Subsequently, the deterior-
ation of cognitive function to PD-MCI is associated with
an extension from frontal regions to a wider involvement of
posterior temporal cortices, most probably as a result of its
multifactorial nature in conjunction with generalized dis-
ruptions of other neurotransmitter systems. In addition,
we propose that the focal thinning in frontal regions
causes a progressive degeneration of the reciprocal cor-
tico-cortical connections between the temporal and frontal
regions (Simons and Spiers, 2003). This notion is supported
by our ﬁnding of additional temporal cortical thinning in
PD-MCI. Furthermore, these patterns of cortical thinning,
particularly the differential involvement of posterior cor-
tical regions in PD-MCI, are also consistent with the neuro-
psychological evolution demonstrated in a different incident
cohort of patients with Parkinson’s disease by the
CamPaIGN study (Williams-Gray et al., 2009). Our study
also provides structural imaging support for the dual-
syndrome hypothesis, which posits that the frontostriatal
deﬁcits relate to dopaminergic deﬁcits and that the devel-
opment of dementia is associated with a more widespread
and posterior pattern of cortical changes (Kehagia et al.,
2012). Finally, we noted an asymmetric pattern of cortical
thinning in the left hemisphere of the PD-NC relative to
healthy controls over 18 months. This ﬁnding suggests
that cortical changes could start initially in one hemisphere
and subsequently extend to the other as cognitive capacity
deteriorates, as observed by our bilateral involvement in
PD-MCI.
The main strengths of this prospective cohort study are
the longitudinal design of an incident cohort, which enables
the investigation of progressive structural changes in
Parkinson’s disease, a topical area of research where cur-
rent knowledge is limited. Our sample size was larger than
in most previous series and all subjects undertook compre-
hensive neuropsychological evaluation. In addition, our
ﬁndings were robust after correction for multiple compari-
sons and accounting for effects of age, which is necessary
given its intimate association with cortical thinning (Salat
et al., 2004) but often overlooked in previous studies.
Several limitations should also be recognized. As with all
ante-mortem studies, we did not have neuropathological
conﬁrmation of Parkinson’s disease. To further protect
against potential misdiagnosis, subjects were reassessed
after 18 months, revealing no change in diagnoses. It
should also be noted that subjects were assessed while
taking their medication, which could inﬂuence cognition
and cortical thickness. The Parkinson’s disease subjects
showed a counter-intuitive improvement in MoCA at
follow-up. This might reﬂect dopaminergic modulation of
executive function, which appears to be highly involved in
some of the subtests of the MoCA. Indeed, there have been
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previous studies showing that executive function may be
improved by levodopa (Mattay et al., 2002). However, as-
sessing patients during their ON state is in keeping with
current clinical practice where many patients are treated
with antiparkinsonian medication following diagnosis if
symptom severity dictates the need to do so. Furthermore,
this will equate to a best ON-state during longitudinal
assessment. Lastly, unlike previous studies, we have
accounted for variance due to levodopa equivalent daily
dose in our imaging analyses.
Although the neuropsychological battery in the present
study has been previously described in detail (Yarnall
et al., 2014), our assessment of visuospatial function was
limited as we only had one representative test (i.e. pentagon
copying item of the MMSE). However, in recent years, the
pentagon copying item of the MMSE has received increas-
ing recognition in its predictive value of dementia in
Parkinson’s disease from several population-based longitu-
dinal studies, suggesting that dementia is heralded by pos-
terior-based cognitive deﬁcits (Williams-Gray et al., 2007,
2009). A recent study has also identiﬁed imaging correlates
of the pentagon copying test in a cohort of Parkinson’s
disease subjects in bilateral posterior regions, such as the
temporo-parietal cortices (Garcia-Diaz et al., 2014). The
inclusion of an additional test of visuospatial ability
would be beneﬁcial in future studies.
Finally, the dichotomization of non-demented
Parkinson’s disease subjects into PD-MCI and PD-NC is
not without potential limitations. A community-based
cohort of 159 newly diagnosed patients with Parkinson’s
disease (CamPaIGN study) revealed deﬁcits in frontostria-
tal-based tasks (12%), temporal lobe-based tasks (8%), and
global cognition (15%) (Foltynie et al., 2004). Given the
near ubiquitous nature and heterogeneity of cognitive def-
icits in Parkinson’s disease, the relative importance of vari-
ous cognitive proﬁles in the development of Parkinson’s
disease dementia remains a topic of continuing debate.
Although executive deﬁcits and attention have been impli-
cated in the development of Parkinson’s disease dementia
(Janvin et al., 2005; Pedersen et al., 2013), a 3.5-year
follow-up of the CamPaiGN cohort further clariﬁed the
evolution of cognitive deﬁcits in Parkinson’s disease by
showing that cognitive deﬁcits with a posterior cortical
basis (i.e. semantic ﬂuency and visuospatial ability) are
most associated with progressive global decline (Williams-
Gray et al., 2007). However, the use of the MDS criteria in
the present literature precludes a ﬁner delineation of
PD-MCI into two subgroups: one that is frontal-striatal
based and another that is posterior cortical based with
greater risks of dementia in Parkinson’s disease.
In conclusion, our combined baseline and follow-up ana-
lyses revealed that PD-MCI is associated with widespread
reductions of cortical thickness at baseline accompanied by
a more severe progression of cortical thinning. In particu-
lar, the frontal and temporal cortical thinning in PD-MCI
may be predictive of progression to Parkinson’s disease
dementia. This study provides strong evidence that
structural MRI can aid early detection of cortical involve-
ment in Parkinson’s disease and target appropriate
intervention.
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